Whereas CAR T cell therapy targeting CD8+ T cells to tumor antigen has shown remarkable efficacy for treating patients with certain B cell driven hematological malignancies (64), ICI has significantly enhanced life-expectation in patients with a broad range of solid tumors (65–68) and became the first-line therapy for advanced melanoma patients, given its improved clinical efficacy and improved safety profile in comparison with conventional cancer therapies (65). This evidence concerns the gene CD8A and neoplasm.